Our Hybrid Platform is Solving Industry Challenges
Traditional methods of producing alkaloid APIs are complex, environmentally challenging and expensive. River Stone Biotech’s manufacturing and process development capabilities couple fermentation with improved chemistry methodology. This combination approach enables flexible intermediates to be taken into more streamlined chemistry conversion processes, driving efficiencies across many criteria. The result is a first-in-kind platform that solves key industry challenges – reducing complexity, waste and cost.
Our Focus
Our priority focus is on the very expensive APIs buprenorphine, naloxone and naltrexone – used in treatments for opioid use disorder, alcohol use disorder, opioid overdose and pain. In line with high prevalence of these indications, we expect an increasing need for production of these life-changing APIs.
Our Focus
View our select investor presentations and scientific publications for the latest information and updates.
View NowWorking together we can create successful partnerships to
enable and expand our API offering.
